88,002 Shares in Disc Medicine, Inc. (NASDAQ:IRON) Bought by Raymond James Financial Inc.

Raymond James Financial Inc. acquired a new position in shares of Disc Medicine, Inc. (NASDAQ:IRON - Free Report) during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor acquired 88,002 shares of the company's stock, valued at approximately $5,579,000. Raymond James Financial Inc. owned approximately 0.30% of Disc Medicine at the end of the most recent reporting period.

Several other large investors also recently made changes to their positions in IRON. Teacher Retirement System of Texas increased its stake in Disc Medicine by 8.9% during the 4th quarter. Teacher Retirement System of Texas now owns 4,857 shares of the company's stock valued at $308,000 after purchasing an additional 396 shares in the last quarter. China Universal Asset Management Co. Ltd. increased its holdings in Disc Medicine by 10.4% during the 4th quarter. China Universal Asset Management Co. Ltd. now owns 6,310 shares of the company's stock worth $400,000 after acquiring an additional 593 shares during the period. Rhumbline Advisers lifted its stake in Disc Medicine by 5.7% in the 4th quarter. Rhumbline Advisers now owns 29,036 shares of the company's stock worth $1,841,000 after purchasing an additional 1,553 shares in the last quarter. JPMorgan Chase & Co. boosted its holdings in Disc Medicine by 16.1% in the 3rd quarter. JPMorgan Chase & Co. now owns 16,255 shares of the company's stock valued at $799,000 after purchasing an additional 2,257 shares during the period. Finally, Legal & General Group Plc increased its holdings in shares of Disc Medicine by 20.8% in the fourth quarter. Legal & General Group Plc now owns 17,688 shares of the company's stock worth $1,121,000 after purchasing an additional 3,051 shares during the period. 83.70% of the stock is currently owned by institutional investors and hedge funds.

Insider Transactions at Disc Medicine

In other Disc Medicine news, CEO John D. Quisel sold 5,574 shares of the stock in a transaction on Tuesday, February 18th. The stock was sold at an average price of $54.58, for a total transaction of $304,228.92. Following the sale, the chief executive officer now directly owns 154,828 shares in the company, valued at approximately $8,450,512.24. This trade represents a 3.48 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, Director Mona Ashiya sold 5,738 shares of Disc Medicine stock in a transaction on Monday, March 24th. The stock was sold at an average price of $54.11, for a total value of $310,483.18. Following the completion of the sale, the director now directly owns 186,541 shares of the company's stock, valued at approximately $10,093,733.51. The trade was a 2.98 % decrease in their position. The disclosure for this sale can be found here. Over the last three months, insiders have sold 361,690 shares of company stock valued at $19,648,094. Insiders own 4.24% of the company's stock.

Wall Street Analysts Forecast Growth

A number of analysts have recently issued reports on IRON shares. Scotiabank lifted their price target on Disc Medicine from $73.00 to $75.00 and gave the company a "sector outperform" rating in a research report on Monday, March 3rd. HC Wainwright reissued a "buy" rating and issued a $118.00 price target on shares of Disc Medicine in a research note on Tuesday, January 21st. TD Cowen assumed coverage on shares of Disc Medicine in a research report on Thursday, February 27th. They set a "buy" rating on the stock. Stifel Nicolaus increased their price target on shares of Disc Medicine from $90.00 to $94.00 and gave the company a "buy" rating in a research report on Friday, January 24th. Finally, Wedbush reissued an "outperform" rating and issued a $90.00 target price (up previously from $83.00) on shares of Disc Medicine in a research note on Tuesday, January 21st. Ten analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat.com, the stock has a consensus rating of "Buy" and a consensus target price of $93.80.

Disc Medicine Trading Up 4.8 %

Disc Medicine stock traded up $2.27 during trading hours on Wednesday, hitting $49.42. 437,945 shares of the stock traded hands, compared to its average volume of 345,087. The company has a market cap of $1.71 billion, a PE ratio of -12.42 and a beta of 0.77. The firm's 50-day moving average price is $48.14 and its two-hundred day moving average price is $55.03. Disc Medicine, Inc. has a one year low of $27.79 and a one year high of $68.73.

Disc Medicine (NASDAQ:IRON - Get Free Report) last announced its quarterly earnings data on Thursday, February 27th. The company reported ($0.98) earnings per share for the quarter, topping analysts' consensus estimates of ($1.06) by $0.08. On average, sell-side analysts expect that Disc Medicine, Inc. will post -4.07 earnings per share for the current fiscal year.

Disc Medicine Profile

Disc Medicine, Inc, together with its subsidiaries, a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases in the United States. The company has assembled a portfolio of clinical and preclinical product candidates that aim to modify fundamental biological pathways associated with the formation and function of red blood cells, primarily heme biosynthesis and iron homeostasis.